Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Stock analysts at Atb Cap Markets reduced their FY2024 EPS estimates for shares of Bradmer Pharmaceuticals in a research report issued on Sunday, January 26th. Atb Cap Markets analyst M. Toner now expects that the company will post earnings of $3.01 per share for the year, down from their previous estimate of $3.63. Atb Cap Markets also issued estimates for Bradmer Pharmaceuticals’ FY2025 earnings at $1.51 EPS.
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported C($0.18) EPS for the quarter, topping analysts’ consensus estimates of C($0.52) by C$0.34.
Read Our Latest Analysis on GLX
Bradmer Pharmaceuticals Price Performance
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- The How and Why of Investing in Gold Stocks
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Top Stocks Investing in 5G Technology
- What Does the Future Hold for Eli Lilly?
- Find and Profitably Trade Stocks at 52-Week Lows
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
